60 Degrees Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Nov 13, 2025, SXTP reported earnings of -2.64 USD per share (EPS) for Q3 25, beating the estimate of -4.93 USD, resulting in a 46.52% surprise. Revenue reached 528.56 thousand, compared to an expected 408.00 thousand, with a 29.55% difference. The market reacted with a -4.88% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were 60 Degrees Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, 60 Degrees Pharmaceuticals, Inc. Common Stock reported EPS of -$2.64, beating estimates by 46.52%, and revenue of $528.56K, 29.55% above expectations.
How did the market react to 60 Degrees Pharmaceuticals, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -4.88%, changed from $1.23 before the earnings release to $1.17 the day after.
When is 60 Degrees Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for 60 Degrees Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on --
analysts, 60 Degrees Pharmaceuticals, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.